This study was developed by the RTI International-University of North Carolina at Chapel Hill (RTI-UNC) Evidence-Based Practice Center under contract to the Agency for Healthcare Research and Quality (AHRQ) (contract No. 290-97-0011), Rockville, MD. We acknowledge at AHRQ the continuing support of David Atkins, M.D., M.P.H., Chief Medical Officer of the AHRQ Center for Practice and Technology Assessment; and Jean Slutsky, P.A., M.S.P.H., Task Order Officer for the USPSTF project.
We are also indebted to our USPSTF liaisons: Mark Johnson, M.D., M.P.H., University of Medicine & Dentistry of New Jersey, Newark, NJ; Jonathan Klein, M.D., M.P.H., University of Rochester, Rochester, NY; Nola Pender, Ph.D., R.N., F.A.A.N., University of Michigan, Ann Arbor, MI; Cynthia Mulrow, M.D., M.Sc., National Program Office for Robert Wood Johnson Generalist Physician Faculty Scholars Program and The University of Texas Health Science Center, San Antonio, TX, for the guidance and substantive contributions.
The investigators deeply appreciate the considerable support and contributions of members of the RTI International staff: Kathleen N. Lohr, Ph.D., EPC Co-director, for technical review and editing of this summary of the evidence, Linda Lux, M.P.A., for substantive assistance and technical review, Sonya Sutton, B.S.P.H., for substantive and editorial work, and Loraine Monroe, for superior secretarial assistance. In addition, we are indebted to staff from the University of North Carolina at Chapel Hill and the Cecil G. Sheps Center for Health Services Research: Carol Krasnov for diligent administrative assistance and coordination, and Timothy S. Carey, M.D., M.P.H., Director of the Sheps Center and Co-Director of the RTI-UNC Evidence-based Practice Center.
1. Padwal R, Straus SE, McAlister FA. Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review. BMJ 2001;322(7292):977-80.
2. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275(20):1571-6.
3. Klein R, Klein BE, Moss SE. The relation of systemic hypertension to changes in the retinal vasculature: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 1997;95:329-48; discussion 348-50.
4. Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D, Krupski WC, Barone GW, Acher CW, Ballard DJ. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997;126(6):441-9.
5. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Washington, DC: Office of Disease Prevention and Health Promotion; 1996. "Screening for hypertension," p. 39-51.
6. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D. Current methods of the U.S. Preventive Services Task Force: a review of the process. Am J Prev Med 2001;20(3 Suppl):21-35.
7. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157(21):2413-46.
8. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
9. Benetos A, Thomas F, Bean K, Gautier S, Smulyan H, Guize L. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med 2002;162(5):577-81.
10. Miura K, Daviglus ML, Dyer AR, Liu K, Garside DB, Stamler J, Greenland P. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001;161(12):1501-8.
11. Ferrucci L, Furberg CD, Penninx BW, DiBari M, Williamson JD, Guralnik JM, Chen JG, Applegate WB, Pahor M. Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile. Circulation 2001;104(16):1923-6.
12. Reeves RA. Does this patient have hypertension? How to measure blood pressure. JAMA 1995;273(15):1211-8.
13. Birkett NJ. The effect of alternative criteria for hypertension on estimates of prevalence and control. J Hypertens 1997;15(3):237-44.
14. McAlister FA, Straus SE. Evidence based treatment of hypertension. Measurement of blood pressure: an evidence based review. BMJ 2001;322(7291):908-11.
15. Perry HM Jr, Miller JP. Difficulties in diagnosing hypertension: implications and alternatives. J Hypertens 1992;10(8):887-96.
16. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, Itoh O, Bando T, Sakuma M, Fukao A, et al. Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements: a pilot study in Ohasama. J Hypertens 1997;15(4):357-64.
17. Myers MG, Haynes RB, Rabkin SW. Canadian hypertension society guidelines for ambulatory blood pressure monitoring. Am J Hypertens 1999;12(11 Pt 1):1149-57.
18. Staessen JA, Beilin L, Parati G, Waeber B, White W. Task force IV: Clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on Ambulatory Blood Pressure Monitoring. Blood Press Monit 1999;4(6):319-31.
19. Perloff D, Sokolow M, Cowan R. The prognostic value of ambulatory blood pressures. JAMA 1983;249(20):2792-8.
20. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. Circulation 1998;98(18):1892-7.
21. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998;31(2):712-8.
22. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994;24(6):793-801.
23. Ohkubo T, Imai Y, Tsuji I, Nagai K, Ito S, Satoh H, Hisamichi S. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: the Ohasama Study. Hypertension 1998;32(2):255-9.
24. Khattar RS, Swales JD, Banfield A, Dore C, Senior R, Lahiri A. Prediction of coronary and cerebrovascular morbidity and mortality by direct continuous ambulatory blood pressure monitoring in essential hypertension. Circulation 1999;100(10):1071-6.
25. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999;282(6):539-46.
26. Little P, Barnett J, Barnsley L, Marjoram J, Fitzgerald-Barron A, Mant D. Comparison of agreement between different measures of blood pressure in primary care and daytime ambulatory blood pressure. BMJ 2002;325(7358):254
27. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000;35(2):539-43.
28. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355(9207):865-72.
29. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145-53.
30. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283(15):1967-75.
31. Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Hum Hypertens 1996;10(1):1-8.
32. Leiter LA, Abbott D, Campbell NR, Mendelson R, Ogilvie RI, Chockalingam A. Lifestyle modifications to prevent and control hypertension. Recommendations on obesity and weight loss. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ 1999;160(9 Suppl):S7-12.
33. Jones DW. Body weight and blood pressure. Effects of weight reduction on hypertension. Am J Hypertens 1996;9(8):50s-4s.
34. Blumenthal JA, Sherwood A, Gullette EC, Babyak M, Waugh R, Georgiades A, Craighead LW, Tweedy D, Feinglos M, Appelbaum M, et al. Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning. Arch Intern Med 2000;160(13):1947-58.
35. Cleroux J, Feldman RD, Petrella RJ. Lifestyle modifications to prevent and control hypertension. 4. Recommendations on physical exercise training. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ 1999;160(9 Suppl):S21-8.
36. Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996;275(20):1590-7.
37. Hooper L, Bartlett C, Davey Smith G, Ebrahim S. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ 2002;325(7365):628
38. Ebrahim S, Smith GD. Lowering blood pressure: a systematic review of sustained effects of non-pharmacological interventions. J Public Health Med 1998;20(4):441-8.
39. Fodor JG, Whitmore B, Leenen F, Larochelle P. Lifestyle modifications to prevent and control hypertension. 5. Recommendations on dietary salt. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ 1999;160(9 Suppl):S29-34.
40. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997;65(2 Suppl):643S-51S.
41. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R, et al. Treatment of mild hypertension study. Final results. Treatment of mild hypertension study research group. JAMA 1993;270(6):713-24.
42. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336(16):1117-24.
43. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344(1):3-10.
44. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, Klag MJ. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997;277(20):1624-32.
45. Gilleran G, O'Leary M, Bartlett WA, Vinall H, Jones AF, and Dodson PM. Effects of dietary sodium substitution with potassium and magnesium in hypertensive type II diabetics: a randomised blind controlled parallel study. J Hum Hypertens 1996;10(8):517-21.
46. Fotherby MD and Potter JF. Long-term potassium supplementation lowers blood pressure in elderly hypertensive subjects. Int J Clin Pract 1997;51(4):219-22.
47. Kawano Y, Minami J, Takishita S, and Omae T. Effects of potassium supplementation on office, home, and 24-h blood pressure in patients with essential hypertension. Am J Hypertens 1998;11(10):1141-6.
48. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001;38(5):1112-7.
49. Linden W, Chambers L. Clinical effectiveness of non-drug treatment for hypertension: a meta-analysis. Ann Behav Med 1994;16:35-45.
50. Spence JD, Barnett PA, Linden W, Ramsden V, Taenzer P. Lifestyle modifications to prevent and control hypertension. (7) Recommendations on stress management. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ 1999;160(9 Suppl):S46-50.
51. Batey DM, Kaufmann PG, Raczynski JM, Hollis JF, Murphy JK, Rosner B, Corrigan SA, Rappaport NB, Danielson EM, Lasser NL, et al. Stress management intervention for primary prevention of hypertension: detailed results from Phase I of Trials of Hypertension Prevention (TOHP-I). Ann Epidemiol 2000;10(1):45-58.
52. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ, Stout R, Vallbona C, Winston MC, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002;288(15):1882-8.
53. Ameling EH, de Korte DF, Man in 't Veld A. Impact of diagnosis and treatment of hypertension on quality of life: a double-blind, randomized, placebo-controlled, cross-over study of betaxolol. J Cardiovasc Pharmacol 1991;18(5):752-60.
54. Mann AH. The psychological effect of a screening programme and clinical trial for hypertension upon the participants. Psychol Med 1977;7(3):431-8.
55. Ambrosio GB, Dissegna L, Zamboni S, Santonastaso P, Canton G, Dal Palu C. Psychological effects of hypertension labeling during a community survey. A two-year follow-up. J Hypertens Suppl 1984;2(3):S171-3.
56. Rudd P, Price MG, Graham LE, Beilstein BA, Tarbell SJ, Bacchetti P, Fortmann SP. Consequences of worksite hypertension screening. Differential changes in psychosocial function. Am J Med 1986;80(5):853-60.
57. Rudd P, Price MG, Graham LE, Beilstein BA, Tarbell SJ, Bacchetti P, Fortmann SP. Consequences of worksite hypertension screening. Changes in absenteeism. Hypertension 1987;10(4):425-36.
58. Rastam L, Ryden L. Work absenteeism and well-being in patients treated for hypertension. Eur Heart J 1987;8(9):1024-31.
59. Polk BF, Harlan LC, Cooper SP, Stromer M, Ignatius J, Mull H, Blaszkowski TP. Disability days associated with detection and treatment in a hypertension control program. Am J Epidemiol 1984;119(1):44-53.
60. Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med 1978;299(14):741-4.
61. Taylor DW, Haynes RB, Sackett DL, Gibson ES. Longterm follow-up of absenteeism among working men following the detection and treatment of their hypertension. Clin Invest Med 1981;4(3-4):173-7.
62. Charlson ME, Alderman M, Melcher L. Absenteeism and labeling in hypertensive subjects. Prevention of an adverse impact in those at high risk. Am J Med 1982;73(2):165-70.
63. Johnston ME, Gibson ES, Terry CW, Haynes RB, Taylor DW, Gafni A, Sicurella JI, Sackett DL. Effects of labeling on income, work and social function among hypertensive employees. J Chronic Dis 1984;37(6):417-23.
64. Alderman MH, Charlson ME, Melcher LA. Labeling and absenteeism: the Massachusetts Mutual experience. Clin Invest Med 1981;4(3-4):165-71.
65. Alderman MH, Melcher LA. Occupationally-sponsored, community-provided hypertension control. J Occup Med 1983;25(6):465-70.
66. Stenn PG, Noce A, Buck C. A study of the labeling phenomenon in school children with elevated blood pressure. Clin Invest Med 1981;4(3-4):179-81.
67. Harlan LC, Polk BF, Cooper S, Blaszkowski TP, Ignatius-Smith J, Stromer M, Mull H. Effects of labeling and treatment of hypertension on perceived health. Am J Prev Med 1986;2(5):256-61.
68. Mulrow CD, Pignone M. How do we best individualize treatment for patients based on their cardiovascular risk profile? In: Mulrow CD, ed. Evidence-based Hypertension. London: BMJ Publishing Group; 2001:117-30.
69. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345(7):479-86.
70. U.S. Department of Health and Human Services. Healthy People 2010. With Understanding and Improving Health and Objectives for Improving Health. 2nd ed. Washington, DC: U.S. Government Printing Office; 2000.
[a] Sheridan: Department of Medicine, Division of General Medicine, University of North Carolina, Chapel Hill and Cecil G. Sheps Center for Health Services Research, and RTI-UNC Evidence-based Practice Center.
[b] Pignone: Department of Medicine, Division of General Medicine, University of North Carolina, Chapel Hill and Cecil G. Sheps Center for Health Services Research, and RTI-UNC Evidence-based Practice Center.
[c] Donahue: Department of Family Medicine, University of North Carolina, Chapel Hill.
This document is in the public domain within the United States. For information on reprinting, contact Randie Siegel, Director, Division of Printing and Electronic Publishing, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850. Requests for linking or to incorporate content in electronic resources should be sent to info@ahrq.gov.
Source: Sheridan S, Pignone M, Donahue K. Screening for High Blood Pressure: Review of the Evidence. Am J Prev Med 2003;25:151-8.Current as of July 2003
Internet Citation:
Sheridan S, Pignone M, Donahue K. Screening for High Blood Pressure: Review of the Evidence. Originally in Am J Prev Med 2003;25:151-8. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/3rduspstf/highbloodsc/hibloodrev.htm
Return to USPSTF Recommendations
U.S. Preventive Services Task Force (USPSTF)
Clinical Information
AHRQ Home Page